|
The ever-evolving field of Drug Design calls for novel technologies and protocols to alter protein specificities, ligand binding and drug potency in order to create new and more effective therapeutics and to speed the design process. The SMi Group’s 6th annual Drug Design Conference will provide a forum where industry leaders will join together to discuss the latest advances in computational chemistry, molecular modelling and structure-based drug design. Hear contributions from an excellent panel of speakers, including: - Dr Jonathan S Mason, Divisional Director, Lundbeck Research DK
- Dr Alexander Alex, Director, Computational Chemistry, Pfizer
- Dr Alexander Hillisch, Director, Medicinal Chemistry, Head of Computational Chemistry, Bayer Healthcare
- Jon Erickson, Principal Research Scientist, Computational Drug Discovery, Eli Lilly
- Dr Kent Stewart, Research Fellow, Abbot Laboratories
- Kamal Azzaoui, Research Scientist II, Novartis
Key issues that will be addressed at the conference include: - VIRTUAL SCREENING: The latest technologies and applications of virtual screening in drug design
- COMPUTATIONAL CHEMISTRY: Employ computational chemistry in docking algorithms and data analysis studies
- STRUCTURE-BASED DRUG DESIGN: The latest applications and protocols that can advance drug design studies,including computational tools, NMR and X-ray crystallography
- QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS: The role of QSAR in predicting pharmacokinetics and metabolism of developing drugs
|
Events Home Page
